IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
- 1 April 2008
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 118 (4), 1398-1404
- https://doi.org/10.1172/jci33522
Abstract
Tumors elicit antitumor immune responses, but over time they evolve and can escape immune control through various mechanisms, including the loss of the antigen to which the response is directed. The escape of antigen-loss variants (ALVs) is a major obstacle to T cell–based immunotherapy for cancer. However, cancers can be cured if both the number of CTLs and the expression of antigen are high enough to allow targeting of not only tumor cells, but also the tumor stroma. Here, we showed that IFN-γ and TNF produced by CTLs were crucial for the elimination of established mouse tumors, including ALVs. In addition, both BM- and non-BM–derived stromal cells were required to express TNF receptors and IFN-γ receptors for the elimination of ALVs. Although IFN-γ and TNF were not required by CTLs for perforin-mediated killing of antigen-expressing tumor cells, the strong inference is that tumor antigen–specific CTLs must secrete IFN-γ and TNF for destruction of tumor stroma. Therefore, bystander killing of ALVs may result from IFN-γ and TNF acting on tumor stroma.This publication has 66 references indexed in Scilit:
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cellsThe Journal of Experimental Medicine, 2007
- Predicting benefit from anti-angiogenic agents in malignancyNature Reviews Cancer, 2006
- Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer ImmunotherapyClinical Cancer Research, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Synergy between tumor immunotherapy and antiangiogenic therapyBlood, 2003
- Immunopotentiating Role of IFN-γ in Early and Late Stages of Type 1 CD8 Effector Cell-Mediated Tumor RejectionClinical Immunology, 2001
- Tumor Necrosis Factor Induces Tumor Necrosis via Tumor Necrosis Factor Receptor Type 1-Expressing Endothelial Cells of the Tumor VasculatureThe American Journal of Pathology, 2000
- Human tumor antigens recognized by T lymphocytes.The Journal of Experimental Medicine, 1996
- Anti‐tumor activity of tumor necrosis factor in combination with interferon‐γ is not affected by prior tolerizationInternational Journal of Cancer, 1995
- The Macrophage as an Effector CellNew England Journal of Medicine, 1980